Recently, more and more evidence has demonstrated that SREBP-1 participates in metabolic reprogramming in different cancer, such as prostate cancer (13), breast cancer (14), and glioblastoma (GBM) (15), which has been a potential target for cancer therapy. This evidence concerns the gene SREBF1 and breast carcinoma.